Diana H. Quan

Sydney, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

ClpC1-targeting peptide natural products differentially dysregulate the proteome of Mycobacterium tuberculosis.

ClpC1-targeting peptide natural products differentially dysregulate the proteome of Mycobacterium tuberculosis.

Journal: Nature communications

Published: November 20, 2024

Beta-lactam combination treatment overcomes rifampicin resistance in Mycobacterium tuberculosis.

Beta-lactam combination treatment overcomes rifampicin resistance in Mycobacterium tuberculosis.

Journal: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

Published: June 17, 2024

Synergistic oral beta-lactam combinations for treating tuberculosis.

Synergistic oral beta-lactam combinations for treating tuberculosis.

Journal: Journal of applied microbiology

Published: March 05, 2024

Lung IL-17A-Producing CD4+ T Cells Correlate with Protection after Intrapulmonary Vaccination with Differentially Adjuvanted Tuberculosis Vaccines.

Lung IL-17A-Producing CD4+ T Cells Correlate with Protection after Intrapulmonary Vaccination with Differentially Adjuvanted Tuberculosis Vaccines.

Journal: Vaccines

Published: December 20, 2023

CXCR3 Provides a Competitive Advantage for Retention of Mycobacterium tuberculosis-Specific Tissue-Resident Memory T Cells Following a Mucosal Tuberculosis Vaccine.

CXCR3 Provides a Competitive Advantage for Retention of Mycobacterium tuberculosis-Specific Tissue-Resident Memory T Cells Following a Mucosal Tuberculosis Vaccine.

Journal: Vaccines

Published: September 05, 2023

Assembly of Immunogenic Protein Particles toward Advanced Synthetic Vaccines.

Assembly of Immunogenic Protein Particles toward Advanced Synthetic Vaccines.

Journal: Small (Weinheim an der Bergstrasse, Germany)

Published: September 22, 2022

Carborane clusters increase the potency of bis-substituted cyclam derivatives against Mycobacterium tuberculosis.

Carborane clusters increase the potency of bis-substituted cyclam derivatives against Mycobacterium tuberculosis.

Journal: RSC medicinal chemistry

Published: May 20, 2022

Potent Bactericidal Antimycobacterials Targeting the Chaperone ClpC1 Based on the Depsipeptide Natural Products Ecumicin and Ohmyungsamycin A.

Potent Bactericidal Antimycobacterials Targeting the Chaperone ClpC1 Based on the Depsipeptide Natural Products Ecumicin and Ohmyungsamycin A.

Journal: Journal of medicinal chemistry

Published: March 16, 2022

Pharmacokinetics and safety of inhaled ivermectin in mice as a potential COVID-19 treatment.

Pharmacokinetics and safety of inhaled ivermectin in mice as a potential COVID-19 treatment.

Journal: International journal of pharmaceutics

Published: February 02, 2022

No smoke without fire: the impact of cigarette smoking on the immune control of tuberculosis.

No smoke without fire: the impact of cigarette smoking on the immune control of tuberculosis.

Journal: European respiratory review : an official journal of the European Respiratory Society

Published: November 19, 2021

Particulate Mycobacterial Vaccines Induce Protective Immunity against Tuberculosis in Mice.

Particulate Mycobacterial Vaccines Induce Protective Immunity against Tuberculosis in Mice.

Journal: Nanomaterials (Basel, Switzerland)

Published: June 30, 2021

Biological and Biochemical Evaluation of Isatin-Isoniazid Hybrids as Bactericidal Candidates against Mycobacterium tuberculosis.

Biological and Biochemical Evaluation of Isatin-Isoniazid Hybrids as Bactericidal Candidates against Mycobacterium tuberculosis.

Journal: Antimicrobial agents and chemotherapy

Published: May 11, 2021

Showing 1-12 of 23

Last Updated: 09/26/2026